摘要
免疫治疗已经在肺癌治疗策略中占据重要地位,其中PD-1/PD-L1免疫检查点抑制剂成为该领域的研究热点。PD-1/PD-L1抑制剂可通过阻断PD-1/PD-L1通路重新激活宿主的抗肿瘤免疫应答,已有大量临床研究证明其可以显著改善多种类型癌症包括肺癌的临床终点。基于各项临床研究成果,目前已有4个PD-1/PD-L1抑制剂——Pembrolizumab、Nivolumab、Atezolizumab、Durvalumab经FDA批准用于非小细胞肺癌或小细胞肺癌的一二线治疗或巩固治疗。文章将对PD-1/PD-L1抑制剂在肺癌临床研究中的进展,包括单药或联合用药的疗效、安全性、疗效预测标志物等方面进行综述,旨在为肺癌免疫治疗的临床应用提供依据。
Immunotherapy has been playing an important role in the treatment strategy of lung cancer,among which PD-1/PD-L1 immune checkpoint inhibitors have become a research hotspot in this field. PD-1/PD-L1 inhibitors can reactivate the host’s antitumor immune response by blocking the PD-1/PD-L1 pathway. Numerous clinical studies have shown that it can significantly improve the clinical endpoint of multiple types of cancers,including lung cancer. Based on the results of various clinical studies,there are four PD-1/PD-L1 inhibitors--Pembrolizumab,Nivolumab,Atezolizumab,and Durvalumab have been approved by the FDA for the first-line,second-line or consolidation treatment of non-small cell lung cancer or small cell lung cancer. This article reviews the progress of PD-1/PD-L1 inhibitors in clinical trials of lung cancer,including the efficacy,safety and predictive biomarkers of single or combined drugs,in order to provide evidence for the clinical application of lung cancer immunotherapy.
作者
王梦玮
徐天蔚
王朝霞
WANG Mengwei;XU Tianwei;WANG Zhaoxia(Cancer Medical Center,the Second Affiliated Hospital of Nanjing Medical University,Nanjing 210011,China)
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2021年第7期1084-1094,共11页
Journal of Nanjing Medical University(Natural Sciences)
基金
国家自然科学基金(81871871)
江苏省科技厅重点研发计划(社会发展)项目(BE2019760)。
